Work

Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

Year: 2026

Type: erratum

Abstract: In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.

Source: Nature Medicine

DOI: 10.1038/s41591-026-04532-1

Authors: Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll, on behalf of the ACCESS Trial Investigators

Institutions: The University of Texas Southwestern Medical Center, Pennington Biomedical Research Foundation, Yale University, Northwestern University, Mayo Clinic, Texas Diabetes & Endocrinology, Alliance for Multispecialty Research (United States)

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $12,690

OpenAlex ID: W7165759591

Cites:

Cited by:

Related to: